| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T880 |
0-65 |
Sentence |
denotes |
Yinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: |
| T881 |
66-94 |
Sentence |
denotes |
Yinhu Qingwen granula, drug: |
| T882 |
95-271 |
Sentence |
denotes |
Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental: |
| T883 |
272-300 |
Sentence |
denotes |
Yinhu Qingwen granula group: |
| T884 |
301-306 |
Sentence |
denotes |
Drug: |
| T885 |
307-328 |
Sentence |
denotes |
Yinhu Qingwen Granula |
| T886 |
329-536 |
Sentence |
denotes |
Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. |
| T887 |
537-635 |
Sentence |
denotes |
The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). |
| T888 |
636-703 |
Sentence |
denotes |
It will be given a 200 ml per time, three times a day, for 10 days. |
| T889 |
704-908 |
Sentence |
denotes |
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. |
| T890 |
909-928 |
Sentence |
denotes |
Placebo comparator: |
| T891 |
929-966 |
Sentence |
denotes |
Yinhu Qingwen granula low‐dose group: |
| T892 |
967-972 |
Sentence |
denotes |
Drug: |
| T893 |
973-1008 |
Sentence |
denotes |
Yin Hu Qing Wen granula (low does). |
| T894 |
1009-1171 |
Sentence |
denotes |
This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). |
| T895 |
1172-1376 |
Sentence |
denotes |
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. |
| T896 |
1378-1399 |
Sentence |
denotes |
II Primary (Day 10): |
| T897 |
1400-1450 |
Sentence |
denotes |
changes in the ratio of PaO2 to FiO2 from baseline |
| T898 |
1451-1477 |
Sentence |
denotes |
Secondary (up to 30 days): |
| T899 |
1478-2254 |
Sentence |
denotes |
PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021 |
